Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing
Authors:
- 1 August 2020
- journal article
- letter
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 46 (8) , 1109-1112
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyBMC Cancer, 2017
- A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell CarcinomasJAMA Dermatology, 2017
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trialThe Lancet Oncology, 2017
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012